B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 89.6%

Neg 89.6% Neu 0% Pos 0%

B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underperform and lowers the price target from $12 to $11.